Highly efficient Chemo/Photothermal therapy alleviating tumor hypoxia against cancer and attenuate liver metastasis in vivo

Zeng, Yun; Zhan, Yonghua; Ma, Jingwen; Liu, Huifang; Li, Hanrui; Yi, Tong; Zhu, Qiangxia; Du, Getao; Zhao, Linfei; Chen, Dan; Chen, Xueli

doi:10.1016/j.cej.2022.137724

Cited by 11 publications

(6 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, the synergistic chemo/PTT was at least 3.53-fold more effective than any single therapy and effectively suppressed tumor liver metastasis after RGD was coupled to CuS NPs, which demonstrated an actively targeting action and enhanced DOX uptake into tumor cells. [34] When combined with targeted chemotherapy, the PTT, which comprised DOX-loaded hollow porous silica nanotubes dotted with CuS NPs and conjugated with lactic acid moieties for tumor targeting, could achieve improved tumor suppression. [35] Using MR/PA dual modality imaging-guided synergistic chemo/PTT, polymer micelles loaded with DOX/Gd-CuS NPs actively targeted hepatocellular carcinoma cells via the affinity of overexpressed E-selectin, leading to substantial tumor suppressive effect in vivo (Figure 3A).…”

Section:  Chemotherapymentioning

confidence: 99%

In vivo synergistic tumor therapies based on copper sulfide photothermal therapeutic nanoplatforms

Wang

et al. 2023

Exploration

Self Cite

View full text Add to dashboard Cite

Tumor cells may be eliminated by increasing their temperature. This is achieved via photothermal therapy (PTT) by penetrating the tumor tissue with near‐infrared light and converting light energy into heat using photothermal agents. Copper sulfide nanoparticles (CuS NPs) are commonly used as PTAs in PTT. In this review, we aimed to discuss the synergism between tumor PTT with CuS NPs and other therapies such as chemotherapy, radiotherapy, dynamic therapies (photodynamic, chemodynamic, and sonodynamic therapy), immunotherapy, gene therapy, gas therapy, and magnetic hyperthermia. Furthermore, we summarized the results obtained with a combination of two treatments and at least two therapies, with PTT as one of the included therapies. Finally, we summarized the benefits and drawbacks of various therapeutic options and state of the art CuS‐based PTT and provided future directions for such therapies.

show abstract

Section:  Chemotherapymentioning

confidence: 99%

In vivo synergistic tumor therapies based on copper sulfide photothermal therapeutic nanoplatforms

Wang

et al. 2023

Exploration

Self Cite

View full text Add to dashboard Cite

show abstract

“…The U.S. Food and Drug Administration (FDA)-approved NBTXR3, HfO 2 nanoparticles (NPs), is dominated by high Z element Hf, which effectively deposits ionizing radiation energy and upregulates oxidative stress within tumors. , In our previous work, we found that Ta NPs have stronger X-ray deposition capability than HfO 2 NPs, which is associated with a higher X-ray deposition coefficient of Ta . Moreover, Ta NPs also have good photothermal conversion efficiency, which can improve the hypoxia of tumors in the form of mild photothermal treatment and further enhance tumor radiosensitivity. − More importantly, Ta-based materials have been used clinically as bone filling materials, dental implants and their surface coatings, and embolic contrast agents. − This indicates that Ta NPs have good biosafety, which is expected to be a promising radiosensitizer for OSCC. However, when the radiosensitizers are injected into tumors in the form of solution, the high interstitial pressure of solid tumors generally leads to leakage of the solution along the needle hole and undesirable aggregation within tumors. , What is more, the radiosensitizers under the interstitial pressure of the tumor may diffuse into the surrounding normal tissues, resulting in unnecessary radiosensitization in the irradiated normal tissue.…”

Section: Introductionmentioning

confidence: 98%

Mussel-Inspired Tantalum Nanocomposite Hydrogels for In Situ Oral Cancer Treatment

Zhao

Dai

et al. 2023

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Oral squamous cell carcinoma (OSCC) is one of the most common oral malignancies. Radiotherapy is the primary noninvasive treatment of OSCC for avoiding surgery-induced facial deformities and impaired oral function. However, the specificity of in situ OSCC limits radiotherapeutic effects because of the hypoxia-induced low radiosensitivity of tumors and the low radiation tolerance of surrounding normal tissues. Here, we design a highly efficient and low-toxic radiosensitization strategy. On the one hand, biocompatible poly(vinyl pyrrolidone)-modified tantalum nanoparticles (Ta@PVP NPs) not only have strong X-ray deposition capability to upregulate oxidative stress but also have photothermal conversion efficiency to improve hypoxia for tumor radiosensitivity. On the other hand, to optimize the spatial distribution of Ta@PVP NPs within tumors, mussel-inspired catechol with bioadhesive properties is grafted on tumor microenvironment-responsive sodium alginate (DAA) to form in situ hydrogels for precision radiotherapy. On this basis, we find that Ta@PVP-DAA hydrogels effectively inhibit OSCC development in mice under photothermal-assisted radiotherapy without facial deformities and damage to surrounding normal tissues. Overall, our work not only promotes the exploration of Ta@PVP NPs as new radiosensitizers for OSCC but also develops a nanocomposite hydrogel system strategy as a promising paradigm for the precision treatment of orthotopic tumors.

show abstract

“…In addition, the heat produced by the PTT drug upon laser irradiation can also contribute to better drug uptake by the cells, thereby boosting the therapeutic potency of the chemo-PTT combination nanodrug. 38 The newly synthesized distinct chemo-PTT INMs were examined for their physicochemical properties, photophysical characteristics, light-to-heat efficiency, singlet oxygen quantum yield, cellular uptake, in vitro cytotoxicity, and apoptosis mechanism to provide insights regarding their potential as combination anticancer nanomedicines. As far as we know, this is the first report employing IL chemistry for developing combination nanomedicine using an FDAapproved drug (DOX•HCl).…”

Section: ■ Introductionmentioning

confidence: 99%

Doxorubicin-Based Ionic Nanomedicines for Combined Chemo-Phototherapy of Cancer

Bashiru,

Macchi,

Forson

et al. 2024

ACS Appl. Nano Mater.

View full text Add to dashboard Cite

Synergistic combination therapy approach offers lots of options for delivery of materials with anticancer properties, which is a very promising strategy to treat a variety of malignant lesions with enhanced therapeutic efficacy. The current study involves a detailed investigation of combination ionic nanomedicines where a chemotherapeutic drug is coupled with a photothermal agent to attain dual mechanisms (chemotherapy (chemo) and photothermal therapy (PTT)) to improve the drug's efficacy. An FDA-approved Doxorubicin hydrochloride (DOX• HCl) is electrostatically attached with a near-infrared cyanine dye (ICG, IR783, and IR820), which serves as a PTT drug using ionic liquid chemistry to develop three ionic material (IM)-based chemo-PTT drugs. Carrier-free ionic nanomedicines (INMs) are derived from ionic materials (IMs). The photophysical properties of the developed combination IMs and their INMs were studied in depth. The phototherapeutic efficiency of the combination drugs was evaluated by measuring the photothermal conversion efficiency and singlet-oxygen quantum yield. The improved photophysical properties of the combination nanomedicines in comparison to their parent compounds significantly enhanced INMs' photothermal efficiency. Cellular uptake, dark and light toxicity studies, and cell death mechanisms of the chemo-PTT nanoparticles were also studied in vitro. The combination INMs exhibited enhanced cytotoxicity compared to their respective parent compounds. Moreover, the apoptosis cell death mechanism was almost doubled for combination nanomedicine than the free DOX, which is attributed to enhanced cellular uptake. Examination of the combination index and improved in vitro cytotoxicity results revealed a great synergy between chemo and PTT drugs in the developed combination nanomedicines.

show abstract

Highly efficient Chemo/Photothermal therapy alleviating tumor hypoxia against cancer and attenuate liver metastasis in vivo

Cited by 11 publications

References 59 publications

In vivo synergistic tumor therapies based on copper sulfide photothermal therapeutic nanoplatforms

In vivo synergistic tumor therapies based on copper sulfide photothermal therapeutic nanoplatforms

Mussel-Inspired Tantalum Nanocomposite Hydrogels for In Situ Oral Cancer Treatment

Doxorubicin-Based Ionic Nanomedicines for Combined Chemo-Phototherapy of Cancer

Contact Info

Product

Resources

About